Gastric Cancer Immunotherapy: Dr. Iqbal’s MATTERHORN Insights

Join Dr. Syma Iqbal, USC Keck Medicine’s GI Oncology Chief, as she unveils gastric cancer immunotherapy breakthroughs from the MATTERHORN trial. Learn how durvalumab with FLOT improves outcomes and explore key biomarkers. Watch now!

Timestamps:
0:00 - Introduction: Dr. Iqbal’s Expertise
1:15 - MATTERHORN Trial Overview
2:30 - Quote: “Any patient who's a candidate for perioperative chemotherapy is a candidate for the addition of durvalumab, as long as they don't have a contraindication to the immunotherapy itself.” - Dr. Syma Iqbal
4:00 - Biomarkers for Personalized Treatment
5:45 - Quote: “The addition of immunotherapy helps our immune system identify those cells that are being evaded by the mechanisms of inhibition of the T cells. That pathway is clearly important in esophagogastric cancer.” - Dr. Syma Iqbal
7:30 - Side Effects and Safety
9:00 - Quote: “The addition in the perioperative setting has now led to a positive outcome and an improvement in event-free survival in our patients.” - Dr. Syma Iqbal
10:30 - Future of Gastric Cancer Care
12:00 - Call to Action & Resources

Video interviews to be posted from this event at these websites...
https://oncologytube.com/tag/moasc/
https://moasc.org/

About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights.

Follow OncologyTube:
eNewsletter: https://oncologytube.com/newsletter/
Twitter:   / oncologytube  
LinkedIn:   / oncologytube-com  
Facebook:   / oncologytube  
Instagram:   / oncologytube  
YouTube:    / oncologytube  

Connect with Us:
Share your thoughts in the comments! Join the discussion.